Work

Abstract CT224: Phase II open-label multi-cohort study evaluating CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemo-refractory solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct224

Authors: Devalingam Mahalingam, Carolyn Moloney, Masha Kocherginsky, Claudie Bosc, Katrina Dobinda, Aparna Kalyan, Sheetal M. Kircher, Therese Davis Brown, Ramya Myneni, Mary F. Mulcahy, Al B. Benson, Navdeep Chandel

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821959

Cites:

Cited by: 1

Related to: 10